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Abstract
Approximately 30% of tumor endothelial cells have over-duplicated (>2) centrosomes,
which may contribute to abnormal vessel function and drug resistance. Elevated levels of
vascular endothelial growth factor A induce excess centrosomes in endothelial cells, but
how other features of the tumor environment affect centrosome over-duplication is not
known. To test this, we treated endothelial cells with tumor-derived factors, hypoxia, or
reduced p53, and assessed centrosome numbers. We found that hypoxia and elevated lev-
els of bone morphogenetic protein 2, 6 and 7 induced excess centrosomes in endothelial
cells through BMPR1A and likely via SMAD signaling. In contrast, inflammatory mediators
IL-8 and lipopolysaccharide did not induce excess centrosomes. Finally, down-regulation in
endothelial cells of p53, a critical regulator of DNA damage and proliferation, caused centro-
some over-duplication. Our findings suggest that some tumor-derived factors and genetic
changes in endothelial cells contribute to excess centrosomes in tumor endothelial cells.
Introduction
Tumor progression requires angiogenesis, a hallmark of cancer development, and tumor ves-
sels enable tumor metastasis by providing a conduit for tumor cell invasion and spread [1, 2].
Although tumor vessels are a critical part of the tumor micro-environment, anti-angiogenic
therapies have had no effect or provided transitory improvement, indicating that tumor vessels
become resistant to angiogenesis inhibitors [3]. Consistent with the lack of effectiveness of
anti-angiogenic therapy, recent studies show that endothelial cells (EC) that line tumor vessels
have genetic abnormalities such as aneuploidy. Aneuploidy is often associated with excess cen-
trosomes, and up to 30% of tumor EC have excess centrosomes [4–6]. Centrosomes form the
microtubule-organizing center (MTOC) in interphase cells to regulate cell migration, polarity,
and adhesion, and they form the spindle poles that segregate chromosomes during mitosis [7].
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Thus tumor EC acquire permanent structural and genetic alterations via excess centrosomes
that likely contribute to the phenotypic and functional abnormalities of tumor blood vessels.
Tumor blood vessels are thought to arise from normal vessels that enter the tumor [8, 9],
suggesting that the environment is responsible for inducing excess centrosomes in EC. Tumor
cells secrete elevated levels of various growth factors [10], and our previous work showed that
elevated levels of vascular endothelial growth factor A (VEGF-A) induce centrosome over-
duplication in EC [11]. However, the frequency of centrosome over-duplication in tumor-
derived EC is significantly higher than that induced by excess VEGF-A [6, 11]. Thus other up-
regulated signaling pathways in the tumor environment likely contribute to centrosome over-
duplication in EC. For example, bone morphogenetic protein (BMP), which is required for
appropriate angiogenesis, is up-regulated in certain cancers [12]. Furthermore, different BMP
ligands such as BMP2, BMP4, BMP6 and BMP7 induce angiogenesis [13], and BMP2 and
BMP4 promote tumor angiogenesis [13].
In addition to growth factors, the tumor environment is hypoxic and has elevated levels of
inflammatory cytokines. The tumor environment is hypoxic in part because of abnormal
tumor blood vessels [14]. Hypoxia activates the hypoxia-inducible factor (HIF) family of tran-
scription factors, which further induce expression of numerous downstream targets, including
VEGF-A [15]. Inflammation is also a hallmark of the tumor environment and is thought to
promote tumor growth [16], perhaps via secretion of angiogenic chemokines such as Interleu-
kin 8 (IL-8) that induce tumor angiogenesis [17]. It is not known whether hypoxia or inflam-
mation promote excess centrosomes in EC.
In this report, we analyzed the effects of specific inputs elevated in the tumor environment
on centrosome over-duplication in EC. We found that elevated levels of some BMP ligands are
sufficient to induce centrosome over-duplication in EC, using BMP receptor 1A and likely via
downstream SMAD signaling. Additionally, hypoxia promoted EC centrosome over-duplica-
tion through a VEGF-A-independent mechanism. In contrast, inflammatory mediators did
not affect centrosome numbers in EC. In addition to environmental factors, down-regulation
of the tumor-suppressor p53 induced centrosome over-duplication in EC. These results indi-
cate that both environmental and genetic factors contribute to centrosome over-duplication in
EC, and may contribute to the high frequencies seen in tumor vessels.
Materials and Methods
Cell culture
Human umbilical vein endothelial cells (HUVEC, Lonza Group cc-2519), human brain micro-
vascular endothelial cells (HBMEC, Cell Systems ACBRI 376) and human umbilical artery
endothelial cells (HUAEC) were cultured in endothelial growth medium-2 (EGM-2, Lonza
Group cc-3162). Human lung microvascular endothelial cells (HMVEC-L, Lonza Group cc-
2527) were cultured in EGM-2 MV (Lonza Group cc-3102). Normal mouse EC (NEC) were
originally isolated from mouse mammary glands and cultured in EGM-2 [6]. Growth factors
or lipopolysaccharide (LPS, List Biological Laboratories 201) were added to cultures at indi-
cated concentrations. Exogenous recombinant growth factors used in this study were VEGFA-
165 (PeproTech 100–20), BMP2 (R&D Systems 355-BM-010), BMP4 (R&D Systems 314-BP-
010), BMP6 (R&D Systems 507-BP-020), BMP7 (R&D Systems 354-BP-010), and Interleukin-
8 (IL-8, PeproTech 200–08). VEGF-A and BMP were used at 200 ng/ml, and IL-8 was added at
indicated concentrations. Culture medium was replaced daily for 4 days, and cells were main-
tained at 30–70% confluence. To study signaling, HUVEC were cultured in Opti-MEM for 4
hr before treatment with 200 ng/ml BMP ligands in Opti-MEM for 30 min. To validate the
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specificity of the HIF1α antibody, HUVEC were treated with 100 μM CoCl2 for 4 hr in EGM-2
prior to fixation and staining.
Lipofectamine RNAiMAX (Life Technologies 13778–150) was used for siRNA transfection
according to manufacturer protocols. siRNAs were: non-targeting siRNA (Life technologies
4390847), BMPR1A siRNA (Life technologies 4392420-s280), BMPR1B siRNA (Life technolo-
gies 4392420-s2043) and BMPR2 siRNA (Life technologies 4390824-s2046).
For hypoxia experiments, HUVEC were cultured in a hypoxia incubator flushed with 2% or
3% O2 for 4 days. The hypoxia incubator digitally sets the percentage of O2 at user-defined lev-
els, and automatically controls the level of O2 by modulating N2 levels, which is supplied
through a nitrogen air tank. 1 μg/ml of recombinant human VEGF Receptor-1 (Flt-1)/Fc
(R&D Systems 321-FL-050) was added to medium to block VEGF-A signaling [18], and the
medium was changed daily. In general, EC were immediately fixed with cold MeOH after hyp-
oxic incubation. To test for translocation of HIF1α, EC were recovered in normoxia for 30
min before fixation. Hypoxic-mimetic agent desferrioxamine (DFO) and a hypoxia incubator
chamber were kindly provided by Dr. Kimryn Rathmell.
Immunofluorescence and microscopy
HUVEC were fixed in ice cold 100% MeOH for 10 min, then stained as previously described
[19]. Briefly, fixed cells were blocked in 5% bovine serum in PBS for 1hr at room temperature
(RT), then incubated with mouse anti-human γ-tubulin (1:5000, Sigma-Aldrich T6557), rabbit
anti-human pericentrin (1:5000, Abcam ab4448), rabbit anti-human pSmad1/5 (1:500, Cell
Signaling 9516) or mouse anti-human HIF1α (1:50, Novus biologicals NB100-105) at 4˚C
overnight. To validate HIF1α antibody specificity, fixed HUVEC were incubated with staining
solution at 4˚C overnight. After washing 3X 5 min in PBS, cells were incubated with secondary
antibodies (1:250), including goat-anti-mouse Alexa 488 (Invitrogen A11029) or goat-anti-
mouse Alexa 594 (Invitrogen A11005), and DRAQ7 (1:1000, Abcam ab109202) or SYTOX
green (1:50,000, Invitrogen S7020), for 2hr at RT. Both primary and secondary antibodies
were diluted in 5% bovine serum in PBS. Centrosome numbers in interphase endothelial cells
were determined using a Zeiss LSM 5 Pascal microscope with a 100X objective. Mitotic cells
were excluded using the DNA marker DRAQ7 in most experiments, and any evidence of
nuclear envelope breakdown and/or chromosome condensation was used as exclusion criteria.
Nuclear pSMAD1/5 and HIF1α fluorescence intensities were quantified in ImageJ using a
mask. Briefly, the DRAQ7 (nucleus) channel from compressed z-stacks was thresholded to
segment nuclei and adjusted into a binary image. Intensity analysis was redirected from the
binary image to the pSMAD1/5 or HIF1α channel by changing the “Set Measurements”
parameter. “Analyze Particles” function was executed to determine pSMAD1/5 and HIF1α
intensity in each nucleus.
Western blot
Western blot analysis was performed as previously described, with slight modifications [11].
Briefly, HUVEC lysates were lysed using RIPA buffer supplemented with protease inhibitor
(Cell Signaling 5871S). Proteins were separated on a 10% sodium dodecyl sulfate–polyacryl-
amide gel, transferred to a PVDF membrane (GE Healthcare, RPN303F), and blocked in 5%
bovine serum albumin (BSA) in PBS with 1% tween-20 (Sigma P2287) for 1h at RT. Primary
antibodies used were: rabbit anti-phospho-Smad1/5 (1:1000, Cell Signaling 9516), rabbit anti-
Akt (1:1000, Cell Signaling 9272), rabbit anti-phospho-Akt (Ser473) (1:1000, Cell Signaling
4060), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204) (1:1000, Cell Signaling 4370), rabbit
anti-ERK 1/2 (1:1000, Cell Signaling 4695), mouse anti-HIF1α (1:500, Novus biologicals
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NB100-105), mouse anti-p53 (1:1000, Abcam ab1101) and rabbit anti-p53 (1:500, Abcam
ab131442). Membranes were incubated with primary antibodies diluted in 1% BSA overnight
at 4˚C. Signal was detected with horseradish peroxidase (HRP) anti-rabbit (1:5000, Invitrogen
G-21234) or HRP anti-mouse (1:30,000, Invitrogen 81–6720), and imaged via Clarity Western
ECL Substrate (Bio-Rad 170–5061). Full original blots are shown (S6 Fig).
Quantitative real-time PCR
HUVEC were collected 48 hr after siRNA transfection, and total RNA was isolated with TRI-
ZOL (Life technologies 15596–026) according to the manufacturer’s protocol. 1 μg of RNA
was used for synthesizing cDNA with iScript (Bio-Rad 1708891). cDNA products were diluted
fivefold. For measuring BMPR1B, BMPR2 and GAPDH, 0.5 ul of diluted samples were used as
templates; for BMPR1A, 5 ul of diluted samples were used. RT-PCR was preformed using iTaq
universal SYBR Green supermix (Bio-Rad 1725121) in a 7900HT fast RT-PCR system (Applied
Biosystems). Primer sequences were: GAPDH (forward: CCTCAAGATCATCAGCAATGCCT
CCT; reverse: GGTCATGAGTCCTTCCACGATACCAA), BMPR1A (forward: AGCTACGCCGGA
CAATAGAA; reverse: CTATGACAACAGGGGGCAGT),BMPR1B (forward: GCCTGCCATAAGT
GAGAAGC; reverse: CTTTCTTGGTGCCCACATTT),and BMPR2 (forward: GGTAAGCTCTTGC
CGTCTTG; reverse: ATCTCGATGGGAAATTGCAG).
Lentivirus infection
Human p53–targeted shRNA (clone ID: V3LHS_333920) with pGIPZ vector was obtained
from Open Biosystems. Mouse p53–targeted shRNA clone (TRCN0000012360) with pLKO.1
vectors were obtained from the UNC Lenti-shRNA Core facility. The centrin-GFP-expressing
lentiviral construct was previously generated [19]. Lentiviruses were made by the UNC Lenti-
shRNA Core facility. Cells were infected with 100 μl/ml lentivirus in 5 ml medium plus 1μg/ml
polybrene (Millipore) overnight at 37˚C, then incubated for 4 days before fixation or collec-
tion. Virus lacking a target sequence (empty vector) was used as a control.
Statistical analysis
The paired or unpaired two-tailed Student’s t-test was used to determine statistical significance
in cases with 3 repeats. The Χ2 test was used to determine statistical significance in cases with 2
repeats. Error bars represent standard deviation from mean between experiments.
Results
Elevated levels of BMP ligands induce excess centrosomes in EC
We began to dissect the different potential inputs to excess centrosome formation from the
tumor environment by introducing elevated levels of different signaling pathways or by genetic
manipulation of normal EC and assessing effects on centrosome over-duplication. Because
BMP ligands regulate angiogenesis and are expressed in the tumor micro-environment, we
asked whether elevated BMP signaling regulates centrosome number in EC. HUVEC treated
with different BMP ligands were stained with anti-γ-tubulin antibodies to label centrosomes,
and EC with different centrosome numbers were clearly identified (S1A Fig). Co-labeling with
centrin-GFP and pericentrin revealed the same centrosome numbers, indicating that de novo
centrosome over-duplication was scored (S1A Fig). As previously described, EC with 3 or
more centrosomes were considered to have excess centrosomes (Fig 1A) [19]. Exposure to
BMP2, BMP6, or BMP7 caused a significant increase in the percentage of HUVEC with excess
centrosomes (Figs 1B, 1C and 2A). This effect was not observed with BMP4 treatment in
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HUVEC (S1B Fig), nor upon treatment with BMP2 or BMP6 in HUAEC, HBMEC or
HMVEC-L (S1C–S1E Fig). These results indicate that some but not all BMP ligands induce
excess centrosomes, and that different EC isolates respond differently to these ligands.
BMP-induced centrosome over-duplication is BMP receptor type 1A
(BMPR1A)-dependent
To understand the mechanism of BMP-induced centrosome over-duplication, we down-regu-
lated BMP receptors in HUVEC. There are several BMP-specific receptors that include type
1A BMP receptor (BMPR1A/ALK3), type 1B BMP receptor (BMPR1B/ALK6), and type 2
BMP receptor (BMPR2) [20]. siRNA targeting of these three receptors efficiently and signifi-
cantly knock-down their mRNA levels (S2A–S2C Fig). The increase in EC with excess centro-
somes seen with BMP2 or BMP6 was blocked by BMPR1A knockdown, but not by BMPR1B
or BMPR2 knockdown (Fig 2A and 2B). These findings suggest that BMPR1A is required for
BMP-induced centrosome over-duplication.
Type 1 and type 2 BMP receptors form hetero-tetramers upon ligand binding that permits
phosphorylation of downstream effectors called receptor-regulated SMAD (R-SMAD), includ-
ing SMAD1 and SMAD5. Phosphorylated R-SMADs bind SMAD4 to translocate into the
Fig 1. BMP2 and BMP7 induce excess centrosomes in EC. (A) Representative images of HUVEC with
normal (#1 and #2) and over-duplicated centrosomes (#3). HUVEC were stained with γ-tubulin for
centrosomes (green) and DRAQ7 for nuclei (blue). (B, C) Frequency of excess centrosomes in HUVEC after
treatment with 200 ng/ml BMP2 (B) or BMP7 (C) for 4 days. Error bars, standard deviation from mean.
Statistics: two-tailed unpaired Student’s t-test. *, p0.05. Scale bars: 1 μm unless indicated otherwise.
doi:10.1371/journal.pone.0168334.g001
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nucleus and modulate gene expression [20]. To further understand the mechanism of BMP-
induced centrosome over-duplication, we examined the phosphorylation of SMAD1/5 by
immunofluorescence. The levels of nuclear phospho-SMAD1/5 (pSMAD1/5) were signifi-
cantly induced by BMP6 treatment in control siRNA, BMPR1B siRNA and BMPR2 siRNA-
treated HUVEC, but not in BMPR1A siRNA-treated cells (Fig 2C and 2D), which was also
confirmed by western blot (Fig 2E). These results suggest that BMPR1A is required for BMP-
induced centrosome over-duplication through downstream R-SMAD activation.
Fig 2. BMP-induced centrosome over-duplication is dependent on BMPR1A. (A, B) Frequency of
excess centrosomes in indicated siRNA-treated HUVEC cultured with vehicle or 200 ng/ml of BMP6 (A) or
BMP2 (B) for 4 days. C, non-targeting control siRNA; R1A, BMPR1A siRNA; R1B, BMPR1B siRNA; R2,
BMPR2 siRNA. (C) Representative images of HUVEC treated with indicated siRNA and vehicle or BMP6 and
stained for phospho-SMAD1/5 (pSMAD1/5, green) and nucleus (DRAQ7, blue). Cells were starved in Opti-
MEM for 4 hr, followed by 30 min treatment with vehicle or BMP6. Only the nuclear pSMAD1/5 is shown (see
Methods for details of mask). (D) Quantification of nuclear pSMAD1/5 in HUVEC treated as indicated. (E)
Western blot of phospho-SMAD1/5 (pSMAD) and total SMAD1 in HUVEC treated as indicated. Cells were
starved in Opti-MEM for 4 hr, then treated with vehicle or BMP6 for 30 min. Error bars, standard deviation from
mean. Statistics: two-tailed paired (A, B) or unpaired (D) Student’s t-test. ns, not significant; *, p0.05; **,
p0.01; ***, p0.001. Scale bars: 10 μm.
doi:10.1371/journal.pone.0168334.g002
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Inflammatory mediators do not promote excess centrosomes in EC
Chronic inflammation-associated signaling, which is activated by up-regulation of cytokines,
is another characteristic of the tumor environment. IL-8 is a pro-inflammatory cytokine that
regulates angiogenesis [21]. To determine if IL-8 promotes centrosome over-duplication in
EC, we treated HUVEC with IL-8, which induced ERK phosphorylation in HMVEC (S3 Fig);
however, these levels of IL-8 did not induce excess centrosomes (Fig 3A). To test more general
effects of inflammation on centrosome over-duplication, HUVEC were treated with lipopoly-
saccharide (LPS), a potent pro-inflammatory agent that promotes secretion of a wide range of
inflammatory mediators [22]. Consistent with the results of IL-8 treatment, LPS treatment did
not induce significant increases in excess centrosomes in HUVEC (Fig 3B). These results indi-
cate that IL-8 and LPS do not induce centrosome over-duplication in EC, suggesting that
inflammatory mediators are not causative agents in generating excess centrosomes in EC.
Hypoxia induces excess centrosomes in EC
In addition to the complex milieu of cytokines and growth factors, tumor environments are
often hypoxic. To determine whether hypoxia induces excess centrosomes in EC, HUVEC
were first treated with the oxygen chelating agent desferrioxamine (DFO), which mimics hyp-
oxia in inducing HIF1α accumulation [23]. Treatment with DFO resulted in a 4-fold increase
in the frequency of excess centrosomes compared to controls (Fig 4A). To further test our
hypothesis, HUVEC were cultured in a 2–3% oxygen environment (hypoxia) for 4 days, then
fixed and stained to assess the frequency of centrosome over-duplication. Hypoxic incubation
led to translocation of HIF1α from the cytoplasm to the nuclear compartment of EC (S4A–
S4C Fig), and also induced accumulation of HIF1α (S4D Fig), indicating the activation of hyp-
oxia pathways. Incubation in 2% or 3% oxygen significantly promoted centrosome over-dupli-
cation compared to normoxic controls (Fig 4B, S4E Fig). These results indicate that a hypoxic
environment is sufficient to induce excess centrosomes in EC.
Hypoxia up-regulates the production and release of pro-angiogenic cytokines such as
VEGF-A in multiple tissues [15]. To determine whether hypoxia-induced centrosome over-
duplication in EC requires VEGF-A signaling, HUVEC were incubated in hypoxic conditions
with recombinant human soluble VEGF Receptor-1 (Flt-1)/Fc to block VEGF-A signaling. Flt-
1/Fc treatment efficiently inhibited ERK phosphorylation induced by VEGF-A (S4F Fig), but
was unable to rescue hypoxia-induced centrosome over-duplication (Fig 4C). This result
Fig 3. Inflammatory mediators do not induce excess centrosomes in EC. (A) Frequency of excess
centrosomes in HUVEC after treatment with indicated factors for 4 days. (B) HUVEC incubated with 10 ng/ml
LPS for 4 days prior to determination of excess centrosome frequency. Results are shown in fold of increase,
and each frequency was normalized to its respective control. Error bars, standard deviation from mean.
Statistics: Two-tailed unpaired Student’s t-test (A), Χ2 test (B). *, p0.05; ns, not significant.
doi:10.1371/journal.pone.0168334.g003
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suggests that hypoxia induces excess centrosomes in EC through VEGF-A-independent
mechanisms.
Inhibition of p53 signaling induces excess centrosomes in EC
Loss or inactivation of p53 induces excess centrosomes in mouse embryonic fibroblasts [24].
Thus, we tested whether p53 attenuation leads to excess centrosomes in EC. A short-hairpin
RNA (shRNA) was used to down-regulate p53 levels in HUVEC (S5A Fig), and HUVEC
infected with p53 shRNA had an approximately 3-fold increase in the percentage of excess cen-
trosomes (Fig 5A). Previous studies demonstrated that mouse tumor stromal cells, including
mouse tumor EC, have an attenuated p53 response [25]. Therefore we asked whether down-
regulation of p53 induced excess centrosomes in mouse EC by infecting immortalized normal
mouse EC (NEC) [6] with p53 shRNA. Down-regulation of mouse p53 also induced excess
centrosomes in NEC (S5B Fig, Fig 5B). These results suggest that down-regulation of p53 con-
tributes to centrosome over-duplication in tumor EC.
Discussion
We previously showed that high levels of the pro-angiogenic growth factors VEGF-A and
bFGF promote excess centrosomes in EC [11]. However, the frequency of EC centrosome
Fig 4. Hypoxia induces excess centrosomes in EC independent of cell-autonomous VEGF-A
signaling. (A) Frequency of excess centrosomes in HUVEC after treatment with 100 μM hypoxic-mimetic
agent desferrioxamine (DFO) for 4 days. (B) Frequency of excess centrosomes in HUVEC after 4 days of
incubation in 2% oxygen. (C) Frequency of excess centrosomes in HUVEC after incubation in 20% or 2%
oxygen for 4 days and indicated treatments. Error bars, standard deviation from mean. Statistics: two-tailed
unpaired Student’s t-test. *, p0.05; ns, not significant.
doi:10.1371/journal.pone.0168334.g004
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over-duplication, even with a combination of both VEGF-A and bFGF, was much less than
that seen in primary isolates of tumor-derived EC [6], suggesting that other aspects of the
tumor environment contribute to pathological centrosome over-duplication. Here we provide
evidence that excess centrosomes in EC occur downstream of numerous tumor-related inputs.
We found that the BMP ligands BMP2, BMP6 and BMP7 significantly induced centrosome
over-duplication, while inflammatory mediators were ineffective. Hypoxia, which is associated
with most solid tumors, induced excess centrosomes in EC through VEGF-A-independent
mechanisms. Besides environmental factors, cell-autonomous perturbation of p53 also pro-
moted excess centrosomes in EC. These findings suggest that multiple inputs contribute to the
high frequency of tumor vessel-derived EC with excess centrosomes.
Elevated levels of some BMP ligands, similar to high levels of VEGF and FGF ligands,
induce excess centrosomes in EC. Interestingly, VEGF and FGF signaling are mediated by
VEGF receptor 2 and FGF receptor, respectively, which belong to the tyrosine kinase receptor
family [26], whereas BMP signals through serine/threonine kinase receptors [27], suggesting
that diverse signaling inputs promote centrosome over-duplication in EC. Our results also
show ligand and cell type specificity of BMP in inducing excess centrosomes: BMP2, BMP6
and BMP7, but not BMP4, significantly induced excess centrosomes in HUVEC, whereas
BMP2 and BMP6 did not significantly affect centrosome numbers in several other human pri-
mary EC.
BMP ligands initiate signal transduction by binding a hetero-tetrameric receptor comprised
of two dimers of type 1 and type 2 receptors [20]. Among a group with specificity for TGFβ
and/or BMP signaling, BMPR1A, BMPR1B and BMPR2 are specific to BMP ligands [20]. Here
we show that knockdown of BMPR1A, but not BMPR1B or BMPR2, inhibits BMP-induced
SMAD1/5 phosphorylation and centrosome over-duplication. BMPR1A is critically involved
in BMP signaling, and BMPR1A knockout mice are embryonically lethal with severe heart
valve and EC defects [28–30]. However, BMPR1B knockout are viable [31]. In line with the in
vivo data, previous in vitro data showed that BMPR1A siRNA, but not BMPR1B siRNA, abro-
gates SMAD1/5 phosphorylation in human microvascular endothelial cells [32]. These results
are consistent with our findings. Interestingly, BMPR2 knockdown did not inhibit SMAD acti-
vation or block BMP ligand-induced centrosome over-duplication, indicating possible redun-
dancy of type 2 receptors in EC. This is also consistent with a previous finding that ablation of
Fig 5. Down-regulation of p53 induces excess centrosomes in EC. (A) Frequency of excess
centrosomes in HUVEC infected with human p53 shRNA. (B) Frequency of excess centrosomes in normal
mouse endothelial cells (NEC) infected with mouse p53 shRNA. Error bars, standard deviation from mean.
Statistics: two-tailed unpaired Student’s t-test. *, p0.05.
doi:10.1371/journal.pone.0168334.g005
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BMPR2 in pulmonary artery smooth muscle cells allows signaling through ActR2A and does
not abolish BMP signaling [33].
Another prominent feature of the tumor environment is a chronic inflammatory response,
which is mediated by infiltration of immune system cells [34]. Tumor inflammation is similar
to inflammation associated with normal physiological processes such as wound healing [34].
Our results suggest that inflammatory mediators do not induce centrosome over-duplication
in EC. Thus, despite being a hallmark of the tumor environment, chronic inflammation is
likely not an input for centrosome over-duplication in tumor EC. This finding also suggests
that during physiological inflammation, EC do not develop excess centrosomes, therefore
maintaining a relatively normal phenotype and function.
Hypoxia upregulates the expression and secretion of growth factors, such as VEGF-A, in
the tumor environment [35]. Here we show that hypoxia induces excess centrosomes in EC.
However, although hypoxia-induced signaling up-regulates VEGF-A, which promotes centro-
some over-duplication [11], our data suggest that hypoxia-induced excess centrosomes in EC
are independent of EC-derived VEGF-A. This indicates that, if tumor EC undergo centrosome
over-duplication as a result of up-regulated VEGF-A signaling in the tumor environment, the
source of the ligand is likely the tumor cells or other non-endothelial stromal cells.
In addition to changes in the tumor environment, tumor EC may also acquire cell-autono-
mous perturbations that promote centrosome over-duplication. Previous studies showed that
tumor stromal cells, including tumor EC, have attenuated p53 activation in response to stress
stimulation [25], and p53 abnormalities have been linked with centrosome over-duplication.
For example, mouse embryonic fibroblasts isolated from p53 knock-out mice possess multiple
copies of functional centrosomes [24]. Here we show that reduced p53 levels induced excess
centrosomes in EC, suggesting that cell autonomous p53 changes contribute to centrosome
over-duplication in tumor EC.
Although up to 30% of primary tumor EC have excess centrosomes [6], our results indicate
that no single environmental factor or down-regulation of p53 alone achieves such a high per-
centage of excess centrosomes in EC [11]. It is possible that in vivo, several inducing factors
combine to achieve the high percentage of excess centrosomes in tumor EC. In summary, we
show that multiple environmental inputs and attenuated p53 contribute to centrosome over-
duplication in EC. This work contributes to our understanding of both normal and tumor
angiogenesis, and provides potential insights for anti-angiogenic therapy.
Supporting Information
S1 Fig. Effects of BMP ligands on human primary EC. (A) HUVEC labeled with centrin-
GFP (green) and stained with γ-tubulin (red) and pericentrin (blue). Different numbers (n) of
centrosomes shown. Nuclear position was determined via DIC and marked with yellow dashed
circles. White dashed squares indicate centrosomes shown in higher magnification to the
right. (B) Frequency of excess centrosomes in HUVEC after treatment with 200 ng/ml of
BMP4 for 4 days. (C-E) Frequency of excess centrosomes in HUAEC (C), HBMEC(D), or
HMVEC-L (E) after treatment with 200 ng/ml of BMP2 or BMP6 for 4 days. Error bars, stan-
dard deviation from mean. Statistics: two-tailed unpaired Student’s t-test. ns, not significant.
Scale bars: 10 μm unless indicated otherwise.
(TIF)
S2 Fig. Validation of BMP receptor siRNAs. (A-C) Relative mRNA levels of BMPR1A (A),
BMPR1B (B), or BMPR2 (C) in HUVEC treated with indicated siRNAs. Cells were collected
48 hr after siRNA treatment. Error bars: standard deviations from mean. Statistics: two-tailed
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unpaired. , p0.05; , p0.001.
(TIF)
S3 Fig. Elevated IL-8 activates ERK phosphorylation. HMVEC were treated with 200 ng/ml
IL-8 or VEGF-A for indicated times, collected, and analyzed for phosphorylated ERK (pERK)
and total ERK.
(TIF)
S4 Fig. Hypoxia activates HIF1α and Flt-Fc blocks VEGF-A signaling. (A) HUVEC were
treated with/without 100 μM CoCl2 for 4 hr before fixation and incubated with/without
HIF1α primary antibody. Only nuclear HIF1α is shown (see Methods for details of mask). (B)
Fluorescence intensity of nuclear HIF1α in HUVEC treated as indicated. (C) HUVEC were
MeOH fixed immediately (lower panel) or after 30-min recovery in normoxia (top panel)
post-hypoxic incubation, then stained for HIF1α (red) and DRAQ7 (DNA, green). (D) West-
ern blot for HIF1α in HUVEC incubated in normoxia or 2% oxygen. (E) Frequency of excess
centrosomes in HUVEC after incubation in 3% O2 for 4 days. (F) HUVEC were treated with
VEGF-A (200 ng/ml) or VEGF-A plus Flt-Fc (1 ug/ml) for 20 min. Cell lysates were collected
and blotted for phosphorylated ERK (pERK) and total ERK. Error bars, standard deviation
from mean. Statistics: two-tailed unpaired Student’s t-test. , p0.05; , p0.001. Scale bars:
20 μm.
(TIF)
S5 Fig. Validation of p53 shRNA. HUVEC (A) or mouse normal endothelial cells (NEC) (B)
were infected with viruses expressing human p53 shRNA or mouse p53 shRNA, respectively.
p53 levels were detected by western blot 4 days after viral infection.
(TIF)
S6 Fig. Original western blot images. Original full blot images corresponding to results in Fig
2E (A), S3 Fig (B), S4D Fig (C), S4F Fig (D), S5A Fig (E) and S5B Fig (F). Cropped areas for
figures are shown in red boxes. Size markers are labeled in red.
(TIF)
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